Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide conjugated to KLH derived from within residues 550 - 650 of Human CLLD8/SETDB2.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4, with 1% BSA|
|Contains||0.02% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50|
|Western Blot (WB)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-19436 targets CLLD8/SETDB2 in IHC (P) and WB applications and shows reactivity with Human samples.
The PA5-19436 immunogen is synthetic peptide conjugated to KLH derived from within residues 550 - 650 of Human CLLD8/SETDB2.
Proteins that contain a SET domain, such as SETDB2, modulate gene expression epigenetically through histone H3 methylation. SETDB2 is likely a histone H3 methyltransferase, as it contains both the active site and flanking cysteine residues required for catalytic activity .
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
C13orf4, CLLD8, CLLL8, DKFZp586I0123, DKFZp761J1217, KMT1F, chronic lymphocytic leukemia deletion region 8; chronic lymphocytic leukemia deletion region gene 8 protein; histone-lysine N-methyltransferase SETDB2; lysine N-methyltransferase 1F
C13orf4; CLLD8; CLLL8; KMT1F; SETDB2